Andere Sprachen Oncolytics Biotech Inc.

Aktien

A2JMW5

CA6823108759

ONC

Verzögert Toronto S.E. Andere Börsenplätze 19:43:18 28.06.2024			% 5 Tage	% 1. Jan.
1.38 ^CAD	0.00%		+0.73%	-22.91%

24.06.	Oncolytics Biotech CEO Matt Coffey lässt sich aus medizinischen Gründen beurlauben	MT
20.06.	Oncolytics Biotech verabreicht ersten Patienten in Studie zur Pelareorep/FOLFIRINOX-Kombinationstherapie bei Bauchspeicheldrüsenkrebs	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program	16:08
Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program	27.06.
Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program	27.06.
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence	24.06.
Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence	24.06.
Oncolytics Biotech Brief: Announcing President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence	24.06.
Oncolytics Biotech Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	20.06.
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX	20.06.
Oncolytics Biotech Brief: Says Dosed First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	20.06.
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	20.06.
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting	24.05.
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer	24.05.
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action	24.05.
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders	16.05.
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial	15.05.
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15.05.
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	13.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Oncolytics Biotech Inc.

Aktien

A2JMW5

CA6823108759

ONC

Andere Sprachen

Filter